Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will release its earnings data after the market closes on Thursday, March 15th. Analysts expect Aurinia Pharmaceuticals to post earnings of C($0.18) per share for the quarter.
Aurinia Pharmaceuticals (AUP) opened at C$6.90 on Thursday. The stock has a market capitalization of $572.39, a price-to-earnings ratio of -4.06 and a beta of 3.34. Aurinia Pharmaceuticals has a 52 week low of C$5.68 and a 52 week high of C$14.17.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/08/aurinia-pharmaceuticals-aup-to-release-earnings-on-thursday.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.